Purpose: Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clinical trials. As CA4P acts on dividing endothelial cells, we hypothesize that CA4P affects vessels of certain sizes. The aim of this study was to evaluate the effect of CA4P by the MRI-based vessel size imaging (VSI).
Introduction
Combretastatin A-4 disodium phosphate (CA4P) is a promising vascular disrupting agent (VDA) in clinical trials (1) . It causes vascular damage and perfusion changes in different tumor types via cytotoxity and antiproliferative effects against mitotic endothelial cells, (2) (3) (4) (5) (6) . Often, the largest effect is seen in the tumor center, because peripheral tumor cells form a viable rim (2, 3, 7) , receiving nutrient supply from the vessels of adjacent normal tissue, which are unaffected by the treatment (8, 9) . The mechanisms by which CA4P causes vascular shutdown, are complex and not completely understood (10) . One interesting observation seen with intravital microscopy was that CA4P mainly decreased the number of small vessels (diameter < 10 mm; ref. 11) . Further information on the vascular effects of the drug will improve the understanding of its mechanisms.
MRI offers a variety of methods to noninvasively estimate vascular characteristics-and thereby the action of CA4P. Dynamic contrast enhanced MRI (DCE-MRI) provides information about blood flow, vessel permeability, interstitial volume, and, depending on the choice of kinetic model, also blood plasma volume. It has been used in both experimental and clinical evaluation of tumor response to CA4P (12) (13) (14) (15) (16) (17) . Another approach is susceptibility-contrast MRI. Intravascular susceptibility contrast has been explored analytically, by simulations, and experimentally with the aim of understanding and using these effects in measurements of cerebral blood flow and blood volume and in functional MRI (18) (19) (20) (21) (22) (23) . A well-described difference in vessel size dependency of the gradient echo and spin echo signals-through the transverse relaxation rates R 2 and R Ã 2 -has led to the novel MRI method vessel size imaging (VSI; refs. [24] [25] [26] [27] [28] [29] caused by an injected contrast agent is proportional to the blood volume independent of the vessel sizes from capillary and above, whereas DR 2 is most sensitive to vessels at capillary size. VSI can be conducted on cerebral dynamic susceptibility-contrast MRI data using standard gadolinium chelates (27) , or iron oxide contrast agent (28) , or in other organs using a contrast agent that remains intravascular for sufficient time to allow R 2 and R Ã 2 measurements at steady state (17, (24) (25) (26) (30) (31) (32) (33) (34) .
We have recently evaluated the CA4P-induced vascular changes by DCE-MRI and susceptibility-contrast MRI (17, 35) . The degree of vascular damage induced 3 hours after CA4P treatment was in agreement with the enhancement of radiation treatment when combined with CA4P. Previously, 2 to 4 hours was shown to be a good time point for monitoring the vascular effects of VDAs in preclinical studies (36, 37) . We hypothesize that the proposed specificity of CA4P for vessels of particular sizes can be shown by VSI. The aim of this study was, therefore, to further characterize the effect of CA4P by VSI in this tumor model, in which we have previously characterized the effect of CA4P by DCE-MRI and other methods. VSI data on the tumor and treatment model used in our previous studies will greatly contribute to the overall knowledge about the tumor vasculature and its complex response to CA4P.
Materials and Methods

Animal and tumor model
C3H mammary carcinomas were implanted into the right rear foot of the female CDF 1 mice. The derivation and maintenance of this tumor have been described previously (38) . Experiments were carried out when the tumors had reached approximately 200 mm 3 in size. Tumor volume was calculated from the formula D1 Â D2 Â D3 Â p/6, in which D1, D2, and D3 represent the 3 orthogonal diameters. The animals were divided into 2 groups; a control group, which received no treatment (n ¼ 21), and a treatment group, which received CA4P treatment (n ¼ 22). All experiments were carried out using nonanesthetized animals and were conducted under institutionally and nationally approved guidelines for animal welfare.
Drug preparation
CA4P (OXiGENE Inc.) was dissolved in saline immediately before each experiment and was kept cold and protected from light and given as a single intraperitoneal injection at a constant volume of 0.02 mL/g body weight at a dose of 250 mg/kg. Sinerem (Laboratoires Guerbet) was diluted in saline to the concentration 1.25 mg Fe/mL and was given intravenously at a dose of 2.5 mg Fe/kg body weight. Hoechst 33342 (Sigma Chemical Co.) was given intravenously at the dose 15 mg/kg.
MRI
MRI was carried out using a 3 Tesla system (Signa Excite HD, General Electric Medical Systems). CA4P-treated mice were scanned 3 hours after drug administration. Mice were restrained in specially constructed lucite jigs with the tumorbearing leg exposed and loosely attached to the jig with tape without impairing the blood supply to the foot. The tail was restrained by tape, and a cannula connected via a 0.38-mm inner diameter line of 16-cm length to a syringe primed with contrast agent solution was applied intravenously in a tail vein. This line was primed with saline to prevent contrast agent from entering the circulation before injection. One or 2 mice were positioned in an upper extremity quadrature radiofrequency coil (Mayo Clinic BC-10 3.0 T, General Electric Medical Systems), and when 2 mice were positioned, their tumors were scanned simultaneously. When a single mouse was scanned, the image slice was positioned similarly through the tumor as for a scan of 2 mice. R 2 and R Ã 2 measurements were conducted on a single oblique slice of 2-mm thickness before and immediately following contrast agent administration. Measurements were conducted using gradient echo and spin echo sequences with TR ¼ 2,000 milliseconds, field of view ¼ 4 Â 4 cm, acquisition matrix 128 Â 128 reconstructed to 256 Â 256, and number of averages ¼ 1. In the gradient echo sequence, the flip angle was 90 , and T E was 6, 10, 20, and 30 milliseconds. The spin echo T E was 15, 30, 40, 45, 60, 80, 120, and 160 milliseconds. For both sequences, the echoes were obtained in 2 excitations. The total scan time following contrast agent administration (17 minutes) was kept within the time interval of constant blood concentration of contrast agent, which was previously estimated by dynamic R 2 and R Ã 2 measurements in 2 separate untreated test tumors, respectively. Following contrast agent administration, R 2 and R Ã 2 remained significantly decreased (one-sample t test on differences) during the 60 minutes of this test (results not shown). Six mice from each treatment group were subject to the histologic analysis described later, the others were euthanized by cervical dislocation after MRI.
MRI data analysis
Analysis was conducted using MATLAB 7.12 (The MathWorks, Inc.). R 2 and R Ã 2 maps were produced by nonlinear
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least squares fitting of the image signal S to the equation SðT E Þ ¼ Sð0Þ Á e ÀT E ÁR Ã 2 following image smoothing by convolution with a Gaussian kernel of 5 voxels in size and a SD of 1. DR ðÃÞ 2 maps were produced by subtracting precontrast maps from corresponding postcontrast maps. Regions of interest (ROI) were defined on the basis of a T 2 -weighted image, and ROI voxels were excluded from the analysis if they displayed unphysiologic values (i.e., DR 2 0, DR
DR 2 ) due to noise. The blood fraction, z 0 , and the vessel size index, R (mean vessel size), were then calculated voxelwise by the equations (25):
where g is the gyromagnetic ratio, Dx is the magnetic susceptibility difference between the intra-and extravascular compartments (in cgs units), B 0 is the applied magnetic field strength, and D is the diffusion coefficient. Dx was interpolated from ref. (26) to 0.128 ppm, and D was assumed to be 0.5 Â 10 À9 m 2 /s based on measurements on the C3H tumor (39) . Quartiles of the parameter values were calculated from each tumor for comparison by Student t test with P < 0.05 considered statistically significant. All tumor voxels in each group were pooled to obtain common parameter histograms for each treatment group.
Histology
Following MRI, the functional perfusion marker Hoechst 33342 was injected intravenously through the line into the tail vein of the mice subject to histology. After 1-minute circulation time, the mice were euthanized by cervical dislocation. The tumors were excised and snap frozen. A 6-mm frozen section of the central part of each tumor was cut in a cryostat at À20 C and mounted to a glass slide. Semiquantitative fluorescence microscopy analysis of the tumor sections was conducted for deriving vascular information from the fluorescent perfusion marker Hoechst 33342 and immunofluorescent histologic detection of the endothelial marker 9F1 [a rat monoclonal antibody to mouse endothelium; Radboud University Nijmegen Medical Centre (Nijmegen, The Netherlands)]. The procedure is previously described by Rijken and colleagues and Hendriksen and colleagues (40, 41) . The following parameters were estimated: relative vascular area, relative perfused tumor area, perfused fraction, number of vascular structures, vessel density, number of perfused vascular structures, perfused vessel density, number fraction of perfused vessels, mean vessel size, and mean perfused vessel size. In short, perfused vascular structures were represented by the result of the logical "AND" operation on the images with the vascular structures (9F1) and the perfused areas (Hoechst 33342). In our data, vessels can have more than 1 perfused area around itself, alternating with nonperfused areas. This leads to an overestimation of the number of perfused vascular structures for this vessel. To correct for this, these perfused vascular structures-belonging to the same vessel-were considered as 1 perfused vascular structure. This was done by image processing using conditional dilation of the image with the perfused vascular structures, resulting in vascular structures that were completely perfused. Student t test was used for comparison with P < 0.05 considered statistically significant. Figure 1 shows a typical example of vessel maps for an untreated tumor. The blood volume (z 0 ) maps showed heterogeneity across the tumor with areas of high blood volume typically in peripheral regions rather than in the tumor center. Maps of mean vessel radius R also showed heterogeneity and indicated that areas of high blood volume and large vessels do not always colocalize. In Fig. 2 are the parameters z 0 , DR 2 , and R shown as mean (AE1 SEM) of individual tumor quartiles. The total blood volume z 0 is a scaling of DR Figure 4A shows histograms of R 2 values obtained before administration of contrast agent. This parameter depends inversely on the amount of free water in, for example, inflammatory tissue. Compared with untreated tumors, the R 2 values of the CA4P-treated tumors were shifted toward higher values with a slightly different distribution shape. The quartiles were all significantly increased (P < 10 À4 ). This may indicate a reduction in extracellular water diffusion due to cell swelling as a consequence of CA4P-induced hypoxia. In Fig. 4B are shown corresponding histograms for DR Ã 2 , which has been related to blood deoxyhemoglobin (42) (43) (44) . CA4P changed the distribution shape toward higher values indicating lower blood oxygenation. The quartiles were all significantly increased (P < 0.05).
Results
Combined images of 9F1 and Hoechst 33342 for a control tumor and a treated tumor are shown in Fig. 5 . They visualize the lower amount of functional vessels following CA4P treatment. The histologically estimated parameters are summarized in Table 1 . The perfused fraction of the vascularized tumor area, number fraction of perfused vessels, relative perfused tumor area, and perfused vessels density, were significantly lower in the CA4P-treated group. Neither of the estimates of mean vessel size showed statistical significance.
Discussion
Our results confirm the vascular targeting properties of CA4P in the C3H mammary carcinoma and further suggest that the drug selectively reduces the proportion of vessels with radii in the range (%20-30 mm) in this tumor type. Bearing in mind that CA4P acts specifically on dividing endothelial cells (2), our results may be explained by different mitotic activities in vessels of different calibers. The results are in agreement with those obtained by WalkerSamuel and colleagues in an orthotopic murine PC3 prostate tumor xenograft 24 hours following treatment with ZD6126, another tubulin-binding agent (45) . Using VSI, they found similar treatment-induced reductions in blood volume, relaxation rates R 2 and R Ã 2 , and mean vessel diameter R. The pre-and posttreatment histogram shapes of R are in qualitative agreement with those obtained in our study supporting a common mechanism of action for the 2 tubulin-binding agents. The peak in the histogram for pretreatment R occurs at a slightly higher vessel size in our study, which may be attributed to scaling problems as addressed later, and while the increases in median and upper quartile of R in our study were not significant, they found significant reductions in percentiles at 60% and below. Our finding is also in agreement with intravital microscopy data on CA4P activity showing that reduction in venule number is largest for small venules (diameter < 10 mm), and that reduction in arteriolar diameter occurs (11) . The distribution of R in the current study may reflect the combination of these vascular effects. The reduction in vessels with radii in the interval (%20-30 mm) could reflect the reported reduction in small venules. As the number of vessels with radii less than 20 mm increased, reduction in vessel diameter could also contribute to the R histogram shape change. The vessel size distribution change did not significantly change the quartiles of R or the histologic mean vessel size estimates. The drug-induced change in z 0 was confirmed by significant reductions in histologic parameters reflecting perfused vessels. It is also in qualitative agreement with our susceptibility imaging (similar blood volume estimates) and DCE-MRI results on the same tumor model (17, 35) and further improved our knowledge about tumor vascular responses to CA4P by providing information on which vessel calibers are targeted by the treatment.
Our study has a number of potential shortcomings. The comparison of individual tumor parameter quartiles (Fig.  2) showed excellent agreement between individual tumor parameter value distributions. Evaluation of the drug effects were, therefore, conducted from pooled histograms. This approach may, however, not necessarily apply in more heterogeneous tumor models or tumor types. Only 1 model was actually used in this study and that was our C3H mammary carcinoma. We focused on this model because our previous studies using DCE-MRI to monitor vascular changes after treatment with CA4P have shown effects in this tumor model that were identical to those recorded in patients with a variety of tumor types using equivalent drug doses (35) .
Absolute values of z 0 are relatively large and may be overestimated; previous estimates of vascular volume in the C3H mammary carcinoma about 200 mm are about 18% (46, 47) . Theoretical reasons may include that equations (1) and (2) are valid for small blood fractions and high Dx only (18, 25) . We chose a clinically relevant dose of contrast Research.
on April 20, 2017. © 2012 American Association for Cancer clincancerres.aacrjournals.org Downloaded from agent, and doses in this range have been shown to overestimate R (26). Other sources of scaling errors may be the assumptions of Dx (for estimation of both z 0 and R) and D (for estimation of R). The adoption of Dx estimated in rats for mice may cause a scaling error because of different blood volumes relative to weight, but this would be small between these species. The overall qualitative evaluation of the drug effect was, however, independent of a systematic scaling. (48, 49) , but this was not the case for CA4P (49) . Twenty-four hours following treatment with CA4P and other VDAs, R Ã 2 decreased. The interpretation of R Ã 2 is complex as both the initial increase and the following decrease are related to perfusion changes; the initial increase is related to larger deoxyhemoglobin levels, and the following decrease related to reduced blood volume. R was distributed differently between the treatment groups showing that certain vessel calibers were affected by CA4P. It should be further investigated whether the distribution of R provides information of angiogenic status or predicts response to VDAs or other treatments.
Despite numerous favorable scientific results being obtained using Sinerem, the clinical development of this agent has now been halted. Other ultrasmall superparamagnetic iron oxide (USPIO) agents have suffered similar fates in the past, but the development of new nanoparticle formulations provide hope that clinically available iron-containing particles can be introduced into the clinic; many of these exhibit prolonged plasma half life, particularly useful for angiographic purposes, or for monitoring antiangiogenic treament. One example is the U.S. Food and Drug Administration (FDA)-approved USPIO compound ferumoxytol (Feraheme, AMAG Pharmaceuticals Inc.) that has recently been shown as a biomarker to identify tumor-associated macrophages (50) .
Conclusions
Estimates of blood fraction and mean vessel size showed a clear response of the tumor model to CA4P. The large change in blood volume is in agreement with histology and our DCE-MRI results on the same tumor model, and the change in distribution of mean vessel size agrees with a study using a different assay. This may be a consequence of different mitotic activity in vessels of different calibers as CA4P acts on dividing endothelial cells only. VSI may be valuable in assessing tumor angiogenesis and prediction of response to VDAs.
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